Full Text View
Tabular View
No Study Results Posted
Related Studies
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
This study has been completed.
Study NCT00039481   Information provided by National Cancer Institute (NCI)
First Received: June 6, 2002   Last Updated: May 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cardiac Toxicity
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
filgrastim
oblimersen sodium
cyclophosphamide
dexrazoxane hydrochloride
doxorubicin hydrochloride
Additional drug interventions recognized in this trial
Doxorubicin
Razoxane
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Cardiovascular Agents
Chelating Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Children's Oncology Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services